Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Blood (2020) 135 (17): 1484–1496.

https://doi.org/10.1182/blood.2019001292

Published: 2020

Includes: Supplemental data

Journal Articles

Therapeutic Disassembly of Leukemogenic Enhancer Complexes

Lauren Forbes, BS, MS, Krasnopolsky Isaac, BA, Gerard Minuesa Dinares, PhD, Michael G. Kharas, PhD, Alex Kentsis, MD PhD

Blood (2018) 132 (Supplement 1): 1352.

https://doi.org/10.1182/blood-2018-99-118807

Published: 2018

Journal Articles

Gene Editing of TRAC Locus Utilizing Megatal Nucleases Increases Expression of Transgenic TCRs Delivered Via Lentiviral Vector-Mediated Gene Transfer

Michael S Magee, PhD, Iulia Diaconu, PhD, Mark Pogson, PhD, Ankit Gupta, PhD, Amy Jensen-Smith, PhD, Brian Collette, BS, Andrew Chavkin, MS, Eli Pasackow, BS, Aaron Edwards, MS, Kevin M. Friedman, Alexander Astrakhan, PhD, Michael T Certo, PhD, Jordan Jarjour, PhD, Richard A. Morgan, PhD

Blood (2017) 130 (Supplement 1): 1906.

https://doi.org/10.1182/blood.V130.Suppl_1.1906.1906

Published: 2017

Journal Articles

Anti-CD19 ARTEMIS TM Therapy Drastically Reduces Cytokine Release without Compromising Efficacy Against Preclinical Lymphoma Models

Hong Liu, PhD, Li Long, MD PhD, Shon Green, PhD, Lucas H Horan, PhD, Bryan Zimdahl, PhD, Cheng Liu, PhD

Blood (2016) 128 (22): 3354.

https://doi.org/10.1182/blood.V128.22.3354.3354

Published: 2016

Journal Articles

Development of a Novel Virus-like Particle (VLP) Vaccine for Personalized B-Cell Lymphoma and Chronic Lymphocytic Leukemia Therapy

Wei Chan, PhD, Thomas Theriault, PhD, Ronald Levy, MD, James Swartz, DSc

Blood (2015) 126 (23): 2748.

https://doi.org/10.1182/blood.V126.23.2748.2748

Published: 2015

Journal Articles

Protein Engineering and in Vitro Characterization of a Factor VIIa Analog with Selective Abrogation of Tissue Factor Binding

Prafull S. Gandhi, PhD, Hanne Grøn, PhD, Helle H Petersen, PhD, Stine L Reedtz-Runge, DVM, PhD, Ole H. Olsen, PhD, Henrik Østergaard, PhD

Blood (2014) 124 (21): 4230.

https://doi.org/10.1182/blood.V124.21.4230.4230

Published: 2014

Journal Articles

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Stefanie Derer, PhD, Pia Glorius, PhD, Martin Schlaeth, Stefan Lohse, PhD, Umesh Muchhal, Ph.D., John Desjarlais, Andreas Humpe, MD, Thomas Valerius, MD, Matthias Peipp, PhD

Blood (2013) 122 (21): 3466.

https://doi.org/10.1182/blood.V122.21.3466.3466

Published: 2013

Journal Articles

Oral Gene Delivery of Factor IX Muteins Formulated As Chitosan Nanoparticles for the Treatment of Hemophilia B

Patricia Quade-Lyssy, Christopher Ungerer, Peter Milanov, PhD, Erhard Seifried, MD, PhD, Jörg Schüttrumpf, MD

Blood (2012) 120 (21): 2048.

https://doi.org/10.1182/blood.V120.21.2048.2048

Published: 2012

Journal Articles

Phase I Study of a New Humanized Anti-CD20 Monoclonal Antibody (LY2469298) in Japanese Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL) Pretreated with Rituximab-Containing Regimen

Michinori Ogura, MD, PhD, Kensei Tobinai, MD, PhD, Toshiki Uchida, MD, PhD, Yukio Kobayashi, MD, PhD, Takashi Oyama, MD, Takashi Watanabe, MD, PhD, Tatsuya Suzuki, MD, PhD, Dai Maruyama, MD, PhD, Masanobu Kasai, MD, Masakazu Mori, MD, Tomomi Matsue, Damien Cronier, PhD, James E Wooldridge, MD, Minori Koshiji, MD, PhD

Blood (2010) 116 (21): 3942.

https://doi.org/10.1182/blood.V116.21.3942.3942

Published: 2010

Journal Articles

Unstable Alpha Hemoglobin Stabilizing Protein as a Cause of Thalassemia: Proof of Concept.

Serge Pissard, Corinne Vasseur, Fabienne Toutain, Muriel Silva, Emmanuelle Faubert-Laugé, Elisa Domingues, Michael Marden, Henri Wajcman, Véronique Baudin-Creuza

Blood (2009) 114 (22): 462.

https://doi.org/10.1182/blood.V114.22.462.462

Published: 2009

Journal Articles

Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant

Laurent O. Mosnier, Antonella Zampolli, Edward J. Kerschen, Reto A. Schuepbach, Yajnavalka Banerjee, José A. Fernández, Xia V. Yang, Matthias Riewald, Hartmut Weiler, Zaverio M. Ruggeri, John H. Griffin

Blood (2009) 113 (23): 5970–5978.

https://doi.org/10.1182/blood-2008-10-183327

Published: 2009

Includes: Supplemental data

Journal Articles

Know your APC

Enrico Di Cera

Blood (2009) 113 (23): 5699–5700.

https://doi.org/10.1182/blood-2009-03-211292

Published: 2009

Journal Articles

Towards a New Therapy for Hemophilia A: Evaluation of Multiple Approaches To Prolong the In Vivo Efficacy of Recombinant Factor VIII.

John E. Murphy, Clark Pan, Baisong Mei, Jonathan Strauss, Hendri Tjandra, Liang Tang, Pamela Esmon, James Newgren, Gary Jesmok, Kyle Landskroner, Mohan Parmathi, Klaus-Peter Radtke, Joanne Severs, John Teare, Haiyan Jiang, Michael Fournel

Blood (2006) 108 (11): 1606.

https://doi.org/10.1182/blood.V108.11.1606.1606

Published: 2006

Journal Articles

Antithrombotic Activity of a Novel Engineered Human Apyrase. Enzymatic Profile, Ex Vivo and In Vivo Properties.

Soon S. Jeong, PhD, Marinus J. Broekman, PhD, Timothy A. Mitsky, BSc, Ridong Chen, PhD, Aaron J. Marcus, MD

Blood (2004) 104 (11): 530.

https://doi.org/10.1182/blood.V104.11.530.530

Published: 2004

Journal Articles

Improving the Efficacy of Rituxan by Rational Protein Engineering.

Greg Lazar, PhD, Wei Dang, PhD, Omid Vafa, PhD, Sher Karki, PhD, Jost Vielmetter, PhD, Stephen Doberstein, PhD, David Carmichael, PhD, Robert Hayes, PhD

Blood (2004) 104 (11): 1405.

https://doi.org/10.1182/blood.V104.11.1405.1405

Published: 2004

NARROW

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Therapeutic Disassembly of Leukemogenic Enhancer Complexes

Gene Editing of TRAC Locus Utilizing Megatal Nucleases Increases Expression of Transgenic TCRs Delivered Via Lentiviral Vector-Mediated Gene Transfer

Anti-CD19 ARTEMIS TM Therapy Drastically Reduces Cytokine Release without Compromising Efficacy Against Preclinical Lymphoma Models

Development of a Novel Virus-like Particle (VLP) Vaccine for Personalized B-Cell Lymphoma and Chronic Lymphocytic Leukemia Therapy

Protein Engineering and in Vitro Characterization of a Factor VIIa Analog with Selective Abrogation of Tissue Factor Binding

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Oral Gene Delivery of Factor IX Muteins Formulated As Chitosan Nanoparticles for the Treatment of Hemophilia B

Phase I Study of a New Humanized Anti-CD20 Monoclonal Antibody (LY2469298) in Japanese Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL) Pretreated with Rituximab-Containing Regimen

Unstable Alpha Hemoglobin Stabilizing Protein as a Cause of Thalassemia: Proof of Concept.

Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant

Know your APC

Towards a New Therapy for Hemophilia A: Evaluation of Multiple Approaches To Prolong the In Vivo Efficacy of Recombinant Factor VIII.

Antithrombotic Activity of a Novel Engineered Human Apyrase. Enzymatic Profile, Ex Vivo and In Vivo Properties.

Improving the Efficacy of Rituxan by Rational Protein Engineering.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only